Protagonist Therapeutics stops ulcerative colitis trial of PTG-100

This article was originally published here

Protagonist Therapeutics said it is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply